Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study

por Phan, Duc Binh, Jourdain, Hugo, González-Quesada, Alicia, Zureik, Mahmoud, Rivera-Díaz, Raquel, Sahuquillo-Torralba, Antonio, Descalzo-Gallego, Miguel Angel, Lunt, Mark, Garcia-Doval, Ignacio, Sbidian, Emilie, Warren, R B, Yiu, Zenas Z N
Publicado 2023

Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis

por Baniandrés-Rodríguez, Ofelia, Vilar-Alejo, Jaime, Rivera, Raquel, Carrascosa, José Manuel, Daudén, Esteban, Herrera-Acosta, Enrique, Sahuquillo-Torralba, Antonio, Gómez-García, Fran J., Nieto-Benito, Lula María, de la Cueva, Pablo, López-Estebaranz, José Luis, Belinchón, Isabel, Ferrán Farrés, Marta, Alsina, Mercè, Fernández-Freire, Lourdes Rodríguez, Carretero, Gregorio, García-Donoso, Carmen, Ballescá, Ferrán, Llamas-Velasco, Mar, Herrera-Ceballos, Enrique, Botella-Estrada, Rafael, Ruiz-Genao, Diana Patricia, Riera-Monroig, Josep, Descalzo Gallego, Miguel Ángel, García-Doval, Ignacio
Publicado 2021